KRYSTAL-1

KRYSTAL-1 is a Phase 1/2 clinical trial investigating the selective KRAS G12C inhibitor adagrasib (MRTX849) in patients with advanced solid tumors.

• Drug: Adagrasib (MRTX849)
• Trial Phase: Phase 1/2
• Target Mutation: KRAS G12C
• Tumor Types Studied:
  • Colorectal Cancer (CRC)
  • Non-Small Cell Lung Cancer (NSCLC)
  • Other solid tumors

• Objective Response Rate (ORR): 19%
• Median Progression-Free Survival (PFS): 5.6 months
• Median Overall Survival (OS): 19.8 months

• ORR: 34%
• Disease Control Rate (DCR): 85.1%
• Median Duration of Response: 5.8 months
• Median PFS: 6.9 months
• Median OS: 15.9 months
• Grade 3–4 Treatment-Related Adverse Events: 27.7%
• Grade 5 Events: None reported

• ORR: 43%
• Median Duration of Response: 8.5 months
• Median PFS: 6.5 months
• Median OS: 12.6 months

• In June 2024, the FDA granted accelerated approval for the combination of adagrasib + cetuximab in patients with previously treated KRAS G12C-mutant metastatic CRC.

• NEJM article on NSCLC arm
• PubMed: CRC data
• FDA approval notice (2024)